石油终于涨了,波斯成了代价
虎嗅· 2025-06-13 21:00
所以美俄在沙特打着俄乌冲突的幌子谈,需要跟欧洲解释吗?毕竟最后三方如果达成合作,最后买单的冤大头必然有欧 洲。 好了,问题又来到了美国身上,懂王终于能调动海军陆战队了,这不合理啊,你真以为加军费能收买的了美军?笑话! 美军要的是捏软柿子疯狂榨汁的战争! 美军早就跟白宫说过,绝不跟东大动手。你政客们会因为各种理由被民粹推动想去搞一把大的,但最后动手的美军可太 清楚自己有几斤几两,跟狠人打,会被打爆浆的。人家好容易混到现在,成了军阀化的势力,两党都要争先巴结,俨然 是帝国的太上皇,好好的日子不过,跑去找虐? 单单就被虐倒还好说,谁还没有被打得满地找牙的黑历史呢? 问题的关键在于,本来针插不进的军方,一旦遭遇了大的溃败,就会有手裹挟民意伸进来,想争夺一下权势了。 这等于是直接打爆了金饭碗,好可怕的后果,不跟!坚决不跟! 还记得懂王刚上任的时候,我写过一篇《聊聊这次美俄会谈》,当时懂王很奇怪地将跟俄罗斯之间的谈判地选在了利亚 德,记住,是沙特的利亚德。照道理,美俄和谈最重要的是跟欧洲达成默契,关沙特啥事? 但美俄沙三家联手起来掌控的是全球的石油,主力联手坐庄,拉高出货,会跟倒霉的买家商量吗? 俄乌冲突停得下来与否,取 ...
华尔街大行之后,沃尔玛、亚马逊也要发行稳定币?
华尔街见闻· 2025-06-13 21:00
沃尔玛、亚马逊等跨国巨头正探索发行自有稳定币,意图节省每年数十亿美元手续费的同时,对传统支 付体系发起最直接的挑战。 据《华尔街日报》周五报道,沃尔玛、亚马逊等跨国巨头近期已开始探索在美国发行自有稳定币的可能 性,在线旅游巨头Expedia和其他大型企业,包括航空公司,同样在讨论发行稳定币的计划。 这一动向并非心血来潮。每年,这些零售商在传统支付系统中支付数十亿美元的手续费,包括客户使用 银行卡购物时产生的交换费。支付结算往往需要数天时间,延迟了商户收到销售收入的时间。稳定币则 提供了更快速结算的可能性,对于拥有海外供应商的商户尤其具有吸引力。 报道称,亚马逊的相关努力仍处于早期阶段,部分讨论集中在推出该公司自己的代币用于在线购物。即 使决定不发行自有稳定币,这些公司也在权衡如何使用外部稳定币,比如通过由某个稳定币发行方领导 的商户联盟。 监管法案成为关键变量 零售巨头们长期以来一直试图推出支付替代方案,以绕过由Visa和万事达卡主导的基于卡片的系统,尽 管其中大多数都未能获得广泛采用。 但这一次可能不同——随着特朗普政府放松加密货币监管,推进GENIUS法案为稳定币建立监管框架, 稳定币正迎来前所未有的发展 ...
东亚药业:首张制剂批文落地,原料药制剂一体化加速兑现
证券时报网· 2025-06-13 21:00
6月13日晚间,东亚药业(605177)(605177.SH)披露一则药品获批公告,公司的左氧氟沙星片近日收到 药监局签发的药品注册证书,正式获得生产、销售资格。公司指出,该药品为公司推进原料药制剂一体 化发展战略下,获批的首个制剂产品,标志着公司原料药制剂一体化发展战略取得重大突破。 而此次获批的左氧氟沙星片,正是东亚药业首个获批的制剂产品。首个制剂产品获批,一方面表明公司 正积极稳步推进募投项目进度,另一方面也有望充分发挥出东亚药业在左氧氟沙星原料药方面的优势, 标志着原料药制剂一体化战略迈入新的阶段。 公告也表明,此次制剂产品获批,将进一步丰富公司产品线,有助于提升公司竞争力,促进公司持续、 稳定、健康地发展。同时为公司后续制剂注册证书申报积累了宝贵的经验。 据了解,"以原料药为中心,往前伸,向后延"是近年来公司坚定的战略发展方向,它不仅有助于公司筑 牢原料药行业市场地位,强化东亚药业在优势药品领域产业链中的核心竞争力,更是公司力争成为国内 原料药、制剂的先导企业,实现国际化一流药企愿景的重要驱动力。 围绕"向后延",2023年公司发行可转债募资近7亿元,其中3.5亿元用于制剂工厂产能建设,拟投产包括 ...
中油工程签115.38亿元人民币订单 预计对未来4—5年营收产生积极影响
证券时报网· 2025-06-13 21:00
6月13日晚间,中油工程(600339)发布中标公告。 从经营业绩看,2024年公司实现营业收入859.17亿元,同比增长6.94%;同期实现归属于上市公司股东 的净利润6.35亿元,同比下降14.80%;去年累计实现新签合同额1250.76亿元,同比增长14.39%。 据披露,近日,公司全资子公司中国石油工程建设有限公司(简称"工程建设公司")与道达尔能源就伊拉 克阿塔维油田气体处理厂项目(简称"阿塔维GPP项目")签署EPSCC承包合同,合同金额16.01亿美元(约 115.38亿元人民币)。 今年一季度,公司实现营业收入171.29亿元,同比增长16.26%;同期实现归属于上市公司股东的净利润 1.94亿元,同比下降19.82%。 2025年5月,工程建设公司收到道达尔能源发来的阿塔维GPP项目授标函,确定工程建设公司为项目中 标人,公司于5月15日发布了"中油工程关于子公司项目中标的公告"。 道达尔能源是一家总部位于法国巴黎的全球综合性能源公司,在全球生产和销售包括石油、生物燃料、 天然气、绿色燃气、可再生能源和电力在内的能源产品,业务遍及百余个国家和地区,致力于以可持续 发展为核心开展项目投资和运营 ...
Pearson to Acquire Career and Technical Education Leader eDynamic Learning
Prnewswire· 2025-06-13 21:00
Acquisition to scale Pearson's position in the Early Careers space LONDON, June 13, 2025 /PRNewswire/ -- Pearson (FTSE: PSON.L), the world's lifelong learning company, today announces that it has entered into an agreement to acquire eDynamic Holdings LP ('eDynamic Learning'), a leading Career and Technical Education (CTE) curriculum solutions provider. eDynamic Learning's comprehensive catalogue of digital courses enables students to follow structured learning pathway programs that prepare them for their fu ...
Millicom (Tigo) Announces Partial Closing of Infrastructure Deal with SBA and Intention to Declare a Special Dividend of $2.50 per Share Representing Around 45% of the Proceeds
Globenewswire· 2025-06-13 21:00
This special dividend is incremental to Millicom's previously announced annual dividend of $3.00 per share, further reflecting the Company's ongoing commitment to shareholder remuneration. This transaction highlights Millicom's strategic commitment to monetizing infrastructure assets, strengthening financial flexibility, and generating sustainable shareholder returns—while reaffirming its disciplined approach to capital structure by maintaining its leverage target range of 2.0-2.5x. Millicom (Tigo) Announce ...
RAPT Therapeutics Announces Effective Date for 1-for-8 Reverse Stock Split
Globenewswire· 2025-06-13 21:00
SOUTH SAN FRANCISCO, Calif., June 13, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (the “Company”), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced that a 1-for-8 reverse stock split of its outstanding shares of common stock will be effective at 11:59 pm Eastern Time June 16, 2025. Following the reverse stock split, the Compan ...
Le Mans Ultimate to Launch Full 1.0 Release on July 22, 2025, Introducing Mercedes AMG LMGT3 Evo, Aston Martin Valkyrie, and a Glimpse Into the Future
Globenewswire· 2025-06-13 21:00
Since launching in Early Access, Le Mans Ultimate has seen rapid evolution. Players have received not only the complete 2023 and 2024 WEC season content, but also a growing suite of systems and tools. These include RaceControl-powered online events and championships, the innovative co-operative mode, broadcast overlays, hosted servers, and, most recently, the arrival of driver swaps, team management, and custom liveries. Additionally, through a significant patching and hotfix programme, much progress has al ...
InspireMD Announces CE Mark Approval for CGuard® Prime Embolic Prevention System (EPS) Under European MDR for the Prevention of Stroke
GlobeNewswire News Room· 2025-06-13 21:00
MIAMI, June 13, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the company has received CE Mark approval under the European Medical Device Regulation (MDR) for the CGuard® Prime EPS. CGuard® Prime was developed incorporating extensive user feedback and optimizes deliverability and deployment of the proven CGuard stent. With its proprietary MicroNet™ mesh, CGuard is designed to reduce both early and la ...
Connect Biopharma Presents Data Supporting Rademikibart at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress
Globenewswire· 2025-06-13 21:00
– Rademikibart significantly improved lung function and asthma control in patients with eosinophilic-driven type 2 asthma – on elevated exhaled nitric oxide (FeNO ≥25 ppb), an additional, independent marker of Type 2 inflammation. The presentations are available on Connect's website under the presentations and publications section. – Data supports ongoing Phase 2 acute exacerbation studies in asthma and COPD; expect to report topline data from both studies in 1H26 – SAN DIEGO, June 13, 2025 (GLOBE NEWSWIRE) ...